Predictors of early progression after curative resection followed by platinum-based adjuvant chemoradiotherapy in oral cavity squamous cell carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Chen CJ, You SL, Lin LH, et al. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol. 2002;32(Suppl):S66–81.
   PubMedGoogle Scholar
• Bernier J, Domenge C, Ozsahin M, et al. European organization for R, treatment of cancer T. postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952.
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Forastiere AA, et al. Radiation Therapy Oncology Group I. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944.
   PubMed Web of Science ®Google Scholar
• Chen WC, Lai CH, Fang CC, et al. Identification of high-risk subgroups of patients with oral cavity cancer in need of postoperative adjuvant radiotherapy or chemo-radiotherapy. Medicine (Baltimore). 2016;95:e3770.
   PubMed Web of Science ®Google Scholar
• Lu HJ, Yang CC, Wang LW, et al. Modified weekly cisplatin-based chemotherapy is acceptable in postoperative concurrent chemoradiotherapy for locally advanced head and neck cancer. Biomed Res Int. 2015;2015:307576.
   PubMed Web of Science ®Google Scholar
• Gillison ML, Blumenschein G Jr., Fayette J, et al. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer. Oncologist. 2018;23:1079–1082.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–1867.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127.
   PubMed Web of Science ®Google Scholar
• Tahara M, Kiyota N, Yokota T, et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 2018;29:1004–1009.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915–1928.
   PubMed Web of Science ®Google Scholar
• Lonneux M, Lawson G, Ide C, et al. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 2000;110:1493–1497. Epub 2000/ 09/13.
   PubMed Web of Science ®Google Scholar
• Kim R, Ock CY, Keam B, et al. Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. BMC Cancer. 2016;16:116. Epub 2016/ 02/18.
   PubMed Web of Science ®Google Scholar
• Moeller BJ, Rana V, Cannon BA, et al. Prospective risk-adjusted [18F] fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol. 2009;27:2509–2515. Epub 2009/ 04/01.
   PubMed Web of Science ®Google Scholar
• Tsan DL, Lin CY, Kang CJ, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012;7:215.
   PubMed Web of Science ®Google Scholar
• Oosting SF, Chen TWW, Huang SH, et al. A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. Oral Oncol. 2016;59:43–49.
   PubMed Web of Science ®Google Scholar
• Szturz P, Wouters K, Kiyota N, et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist. 2017;22:1056–1066.
   PubMed Web of Science ®Google Scholar
• Fesneau M, Pointreau Y, Chapet S, et al. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck cancer: results of GORTEC phase II study. Int J Radiat Oncol Biol Phys. 2010;76:154–163.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, et al. Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity. Oral Oncol. 2020;105:104673.
   PubMed Web of Science ®Google Scholar
• Hsieh MY, Chen G, Chang DC, et al. The impact of metronomic adjuvant chemotherapy in patients with advanced oral cancer. Ann Surg Oncol. 2018;25:2091–2097.
   PubMed Web of Science ®Google Scholar
• Doostparast Torshizi A, Wang K. Next-generation sequencing in drug development: target identification and genetically stratified clinical trials. Drug Discov Today. 2018;23:1776–1783.
   PubMed Web of Science ®Google Scholar
• Liu SA, Wong YK, Lin JC, et al. Impact of recurrence interval on survival of oral cavity squamous cell carcinoma patients after local relapse. Otolaryngol Head Neck Surg. 2007;136:112–118. Epub 2007/ 01/11.
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Clark JR, Ahmadi N, et al. Prognostic significance of disease-free interval in head and neck cutaneous squamous cell carcinoma with nodal metastases. Head Neck. 2013;35:1138–1143. Epub 2012/ 11/16.
   PubMed Web of Science ®Google Scholar
• Chawla S, Kim S, Loevner LA, et al. Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2011;32:778–784. Epub 2011/ 02/26.
   PubMed Web of Science ®Google Scholar
• Chauhan SS, Kaur J, Kumar M, et al. Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer. Oncogenesis. 2015;4:e147. Epub 2015/ 04/22.
   PubMed Web of Science ®Google Scholar
• Wong SJ, Heron DE, Stenson K, et al. Locoregional recurrent or second primary head and neck cancer: management strategies and challenges. Am Soc Clin Oncol Educ Book. 2016;35:e284–e92. Epub 2016/ 06/02.
   PubMedGoogle Scholar
• Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–2561. Epub 2007/ 12/21.
   PubMed Web of Science ®Google Scholar
• Belbin TJ, Singh B, Smith RV, et al. Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2005;131:10–18. Epub 2005/ 01/19.
   PubMed Web of Science ®Google Scholar
• Loree TR, Strong EW. Significance of positive margins in oral cavity squamous carcinoma. Am J Surg. 1990;160:410–414.
   PubMed Web of Science ®Google Scholar